Download PDF
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2018; 54(02): 096-105
DOI: 10.1055/s-0040-1712792
Original Article

Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation

Lalit Kumar
Department of Medical Oncology Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

ABSTRACT

Prognosis of multiple myeloma (MM) has improved during the past two decades. This has been attributed to the better understanding of the biology of disease leading to introduction of two new classes of molecules, namely immune-modulators (e.g. thalidomide, lenalidomide), and proteasome inhibitors (e.g. bortezomib), use of high dose chemotherapy and autologous stem cell transplantation (ASCT) and better supportive care. Current management of myeloma for young patients (≤65 years) includes initial induction therapy followed by consolidation with ASCT followed by maintenance therapy with low dose thalidomide or lenalidomide or bortezomib for 1-2 years.

The choice of initial therapy for patients of MM is based upon their eligibility for ASCT which in turn is based on their age and major co-morbid conditions pertaining to cardiac and renal systems. Patients who are ≤65 years of age (or 65 to 70 years) with no major co-morbid conditions are considered potential candidates for ASCT. Four cycles of induction therapy are administered; a combination of 3 drugs (bortezomib, thalidomide, and dexamethasone (BTD) or bortezomib, lenalidomide, and dexamethasone (BLD) or bortezomib, cyclophosphamide and dexamethasone (BCD) is associated with higher complete response (CR) (approx. 30-40%) and very good partial response (VGPR) and better progression free survival (PFS). Further consolidation with ASCT results in CR rates of 50%–70%; patients who achieve CR, have improved event-free and overall survival. Our initial experience with 225 ASCT supports these observations.

It is now possible to individualize therapy in a given patient. For example, for patients with renal failure (present in 20-30% of patients at diagnosis) ––bortezomib, dexamethasone and/or doxorubicin combination could be an option; for patients with pre-existing peripheral neuropathy––lenalidomide and dexamethasone is preferred; for patients at high risk of venous thrombo-embolism bortezomib- based regimens can be used safely. Treatment with bortezomib or bortezomib + lenalidomide for patients with poor cytogenetics (chromosome deletion t(4;14), t(14;16), 17p–) appears to result in an outcome similar to that in patients without these abnormalities.

In conclusion, from being incurable, myeloma is now a chronic illness. Along with earlier diagnosis, improved treatment and better management of complications have resulted in longer disease control and survival with a better quality of life. Novel agents have provided an opportunity to tailor therapy in an individual patient. Further research is needed to improve outcome for patients who fail to achieve complete response, those with ISS stage III, and extra-medullary disease. Availability of oral proteasome inhibitors and monoclonal antibodies (e.g. IL-6 receptor) are likely to expand choice of agents for maintenance therapy in future.



Publication History

Article published online:
08 May 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 India State-Level Disease Burden Initiative Cancer Collaborators (2018). The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990-2016. Lancet Oncol 19(10):1289-1306.
  • 2 Kumar L, Verma R, Radhakrishnan VR (2010). Recent advances in the management of multiple myeloma. Natl Med J India 23(4): 210-218.
  • 3 Kumar SK, Rajkumar SV, Dispenzieri A, et al (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5): 2516-2520.
  • 4 Richter J, Jagannath S (2018). Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. Clin Lymphoma Myeloma Leuk 18(11): 693-702.
  • 5 Moreau P, Attal M, Facon T (2015). Frontline therapy of multiple myeloma. Blood 125: 3076-3084.
  • 6 Harousseau JL, Attal M, Avet-Loiseau H, et al (2010). Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28(30): 4621-4629.
  • 7 Cavo M, Tacchetti P, Patriarca F, et al; GIMEMA Italian Myeloma Network (2010). Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376: 2075-2085.
  • 8 Rosiñol L, Oriol A, Teruel AI, et al; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group (2012). Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120(8):1589-1596.
  • 9 Moreau P, Avet-Loiseau H, Facon T, et al (2011). Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118: 5752-5758.
  • 10 Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al (2012). Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30(24): 2946-2955.
  • 11 Kumar L, Mookerjee A, Sharma A, Gupta R, Sharma OD, Srinivas V (2015). Low dose dexamethasone plus lenalidomide (Len-dexa) versus thalidomide (Thal-dexa) as induction therapy for newly diagnosed patients of multiple myeloma: a phase III, randomized study. Clin Lymphoma Myeloma Leuk 15(suppl 3): e146.
  • 12 Mookerjee A, Gupta R, Jasrotia S, et al (2017). Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly Diagnosed Multiple Myeloma -a Randomized Phase III Study. Blood 130(suppl 1): 906.
  • 13 Palumbo A, Cavallo F, Gay F, et al (2014). Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10): 895-905.
  • 14 Gay F, Oliva S, Petrucci MT, et al (2015). Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomized, multicentre, phase 3 trial. Lancet Oncol 16: 1617-1629.
  • 15 Attal M, Lauwers-CancesV, Hulin C, et al; IFM 2009 Study (2017). Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376: 1311-1320.
  • 16 Cavo M, Palumbo A, Zweegman S, et al (2016). Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). J Clin Oncol 34: 15(suppl).
  • 17 Dhakal B, Szabo A, Chhabra S, et al (2018). Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol 4(3): 343-350.
  • 18 Attal M, Harousseau JL, Leyvraz S, et al; Inter-Groupe Francophone du Myélome (IFM) (2006). Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 108: 3289-3294.
  • 19 Barlogie B, Pineda-Roman M, van Rhee F, et al (2008). Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112(8): 3115-3121.
  • 20 Spencer A, Prince HM, Roberts AW, et al (2009). Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27: 1788-1793.
  • 21 Lokhorst HM, van der Holt B, Zweegman S, et al; Dutch-Belgian Hemato-Oncology Group (HOVON) (2010). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115:1113-1120.
  • 22 Morgan GJ, Gregory WM, Davies FE, et al; National Cancer Research Institute Haematological Oncology Clinical Studies Group (2012). The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and metaanalysis. Blood 119(1): 7-15.
  • 23 Stewart AK, Trudel S, Bahlis NJ, et al (2013). A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 121: 1517-1523.
  • 24 Attal M, Lauwers-Cances V, Marit G, et al; IFM Investigators (2012). Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1782-1791.
  • 25 McCarthy PL, Owzar K, Hofmeister CC, et al (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770-1781.
  • 26 Rosiñnol L, Oriol A, Teruel AI, et al (2012). Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide vs thalidomide vs alfa2b-interferon: final results of a phase 3 PETHEMA/GEM randomized trial. ASH annual meeting abstracts (Abstract). Blood 120(21).Abstract 334.
  • 27 Fayers PM, Palumbo A, Hulin C, et al; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato -Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network (2011). Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118(5):1239-1247.
  • 28 Facon T,Mary JY, Hulin C, et al; Intergroupe Francophone du Myélome (2007). Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594): 1209-1218.
  • 29 Morgan GJ, Davies FE, Gregory WM, et al; NCRI Haematological Oncology Study Group (2011). Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118(5): 1231-1238.
  • 30 San Miguel JF, Schlag R, Khuageva NK, et al; VISTATrial Investigators (2008). Borte zomib plus melphalan and prednisone for initial treatment of multiple myeloma. Engl J Med 359(9): 906-917.
  • 31 Palumbo A, Hajek R, Delforge M, et al; MM-015 Investigators (2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366(19): 1759-1769.
  • 32 Palumbo A, Bringhen S, Rossi D, et al (2010). Bortezomib -melphalan prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalanprednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28(34): 5101-5109.
  • 33 Palumbo A, Bringhen S, Larocca A, et al (2014). Bortezomib -melphalan prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalanprednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 32(7): 634-640.
  • 34 Mateos MV, Oriol A, Martínez-López J, et al (2010). Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11(10): 934-941.
  • 35 Mateos MV, Oriol A, Martínez-López J, et al (2012). Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120(13): 2581-2588.
  • 36 Benboubker L, Dimopoulos MA, Dispenzieri A, et al; FIRST Trial Team (2014). Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371(10):906-917.